Synthetic Biology (SynBio) in Drug Discovery and Next-generation Therapeutics

Description

Disruptive Technology Advances in SynBio Foster a Thriving Stakeholder Ecosystem and Accelerate Biopharma Developments

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening and easing drug discovery. Its contribution to therapeutics has resulted in the design and development of more sustainable and stable therapies. Emerging and promising SynBio tools, such as gene circuits and CRISPR systems, enable the development of next-generation cell therapies, antibodies, and engineered organisms with therapeutic effects. The rise in next-generation therapeutics will be evident in the coming years, especially in developing CAR-T cell immunotherapy using Synbio, as it can provide accuracy and personalization.

Frost & Sullivan notes a rise in the SynBio start-up ecosystem across regions as the world moves toward precision medicine. Intense R&D efforts are ongoing in academia, start-ups, and big pharmaceutical companies toward developing SynBio-driven therapies for cancer, infectious diseases, and rare diseases.

Therapeutics biomanufacturing also widely uses SynBio platforms, allowing companies to scale therapeutics based on commercial requirements cost-efficiently. Technology developments will boost the global adoption of SynBio tools, encourage the funding ecosystems, and move toward high-growth opportunities.

Information provided in this report includes the following:

Growth drivers and restraints (2023-2027)
Developments in SynBio technologies supporting drug discovery
Critical challenges in developing SynBio therapeutics and the steps taken to address them
Global market participants with potential

Product Code: DAA1

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on SynBio in the Drug Discovery and Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Growth Opportunity Analysis

SynBio Emerges as a Promising Tool in R&D
Growth Drivers
Growth Restraints
Scope of Analysis
Segmentation
Technology Maturity
Emerging Companies, 2020-2022
Trends
Key Findings

Technology Innovations and R&D Scenario in Drug Discovery

Gene Circuits and CRISPR Systems Identify Novel Targets
SynBio Platforms Accelerate the Design and Development of Advanced Therapeutics
Role of SynBio Approaches in the Drug Discovery Pipeline
Target Identification and Drug Molecule Screening Using SynBio-driven Approaches
Advanced CRISPR Systems for Improved Drug Target Screening
Complex Gene Circuits Act as a Tool for Real-time Monitoring of Drug Discovery
Advanced Synthetic Circuit Platforms Enable High-throughput Drug Screening and Selection
Organ-on-a-chip and Organoid Systems Speed SynBio-driven Drug Discovery
Improving the Design of SynBio Tools to Address Challenges in Drug Discovery
The Growing Network of SynBio-driven Drug Discovery Companies

Technology Innovations and R&D Scenario in Therapeutics

Developing Next-generation Therapeutics Using SynBio Tools
Controlled Therapeutic Responses Achieved Using SynBio Tools
SynBio Platform Adoption Can Transform Global Disease Treatment
Developing Advanced Therapeutics and Vaccines with SynBio Tools
Industry Players Developing Advanced Therapeutics and Vaccines Using SynBio Tools
SynBio Tools Enable the Development of Smart Cell Therapies
Logic Gates Improve the Engineered Cellular Activity with a Precise Switch On/Off Mechanism
R&D Efforts Focus on Developing Suitable SynBio Circuit/System
R&D Players Developing Programmable Medicine Using Gene Circuits
Multifunctional Chassis Organisms Used as Therapeutics Improve Scalability and Delivery
Developing Synthetically Engineered Microbiome Therapies
Engineered Microorganisms n Functioning as Live Therapeutics

SynBio Tools Facilitating Drug Discovery and Scaling Up Therapeutic Production

Biosensors Identify Drug Targets and Release Therapeutics with Sensitivity
Cell-free Biomanufacturing of Therapeutics Using Gene Circuits
Growing Applications and Demand for Cell-free Biomanufacturing Systems

Funding and Partnerships Landscape

Encouraging Global Funding Activities to Boost the Growth f SynBio Platforms
Growing Mergers & Acquisitions o Improve SynBio Platform Capabilities
Growing Partnerships Between SynBio Therapy Developers and Pharmaceutical Companies
Global SynBioPlatforms or Accelerated Drug Discovery and Therapeutics

The Road Ahead

Gap Analysis for SynBio-based Therapies
Living ell Therapeutics to Release Therapies Based on Gene Circuits

Growth Opportunity Universe

Growth Opportunity 1: Improve the Long-term Efficiency of CAR-T Cell Therapies Using Synthetic Gene Circuits
Growth Opportunity 2: Foster Collaborations to Build Convergent SynBio Platforms
Growth Opportunity 3: Streamline Regulatory Pathways for Using Synthetic Gene Circuits in Therapeutics

Appendix

Advanced SynBio DBTL Cycle Speeds Drug Discovery

Next Steps

Your Next Steps
Why Frost, Why Now?
Legal Disclaimer